According to Benzinga Pro, Globus Medical's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers. Did you ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Globus Medical GMED recently launched the COHERE ALIF Spacer, the first Porous PEEK interbody spacer for anterior lumbar interbody fusion (ALIF) surgery. Additionally, the company introduced Modulus ...

2025 Financial Guidance and Fourth-Quarter 2024 Earnings Conference Call and Webcast As previously announced on February 6, 2025, given the pending acquisition of Nevro by Globus Medical ...

Fourth-Quarter 2024 Business Highlights and Recent Developments On February 6, 2025, Nevro and Globus Medical (NYSE: GMED) announced that they had entered into a definitive agreement for Globus ...

Fourth-Quarter 2024 Business Highlights and Recent Developments On February 6, 2025, Nevro and Globus Medical (NYSE: GMED ) announced that they had entered into a definitive agreement for Globus ...